Phenotypes Associated with This Genotype

Genotype
MGI:6515783

• Allelic Composition: Sppl3^tm1Itl/Sppl3^tm1Itl; Ncr1^{tm1.1(icre)Viv}/Ncr1⁺
• Genetic Background: involves: 129S/SvEv * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal NK cell differentiation ( J:280182 )

• mice show subtle changes in the expression of NK cell surface receptors and a defect in NK cell maturation with a 5-fold reduction of CD27+CD11b+ NK cells in spleen and a 2.7-fold loss of CD27+CD11b+ NK cells in the bone marrow

increased immature NK cell number ( J:280182 )

• mice show a 1.3-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen

decreased NK cell number ( J:280182 )

• number of NK cells (Lin-CD122+DX5+) is decreased 4-fold in spleen and 1.5-fold in the bone marrow

decreased mature NK cell number ( J:280182 )

• mice show a 9-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 4-fold loss of CD27-CD11b+ NK cells in the bone marrow

abnormal NK cell physiology ( J:280182 )

• mice show a 2-fold reduction in the % of proliferating Ki67+CD11b- NK cells in the bone marrow, with no change in the % of Ki67+CD11b+ cells

• splenic CD11b- NK cells show no change in Ki67 staining, and even a small increase in the CD11b+ fraction relative to controls (10.8% vs 6.8%)

• annexin V staining showed a modest reduction of cell death CD11b- NK cells in the bone marrow relative to controls (10% vs 14%) but no significant change in splenic CD11b- NK cells

• CD11b+ NK cells show a 2-fold increase in annexin V staining in the bone marrow and a 3-fold increase in spleen

• however, activation of mTOR in response to IL-15 stimulation is normal in immature NK cells

impaired natural killer cell mediated cytotoxicity ( J:280182 )

• mice exhibit reduced clearance of MHC class I-deficient tumors in vivo; 48 h after i.p. injection, recovery of RMA/s tumor cells is 6.5% versus 1.8% in control mice

• in an in vitro YAC-1 target lysis assay, splenic NK cells (DX5+) show 53% of the cytotoxic activity seen in control mice at a 2:1 E:T ratio

hematopoietic system

abnormal NK cell differentiation ( J:280182 )

• mice show subtle changes in the expression of NK cell surface receptors and a defect in NK cell maturation with a 5-fold reduction of CD27+CD11b+ NK cells in spleen and a 2.7-fold loss of CD27+CD11b+ NK cells in the bone marrow

increased immature NK cell number ( J:280182 )

• mice show a 1.3-fold increase in the number of immature CD27+CD11b- NK cells in bone marrow but no significant change in spleen

decreased NK cell number ( J:280182 )

• number of NK cells (Lin-CD122+DX5+) is decreased 4-fold in spleen and 1.5-fold in the bone marrow

decreased mature NK cell number ( J:280182 )

• mice show a 9-fold reduction of mature CD27-CD11b+ NK cells in spleen, and 4-fold loss of CD27-CD11b+ NK cells in the bone marrow

abnormal NK cell physiology ( J:280182 )

• mice show a 2-fold reduction in the % of proliferating Ki67+CD11b- NK cells in the bone marrow, with no change in the % of Ki67+CD11b+ cells

• splenic CD11b- NK cells show no change in Ki67 staining, and even a small increase in the CD11b+ fraction relative to controls (10.8% vs 6.8%)

• annexin V staining showed a modest reduction of cell death CD11b- NK cells in the bone marrow relative to controls (10% vs 14%) but no significant change in splenic CD11b- NK cells

• CD11b+ NK cells show a 2-fold increase in annexin V staining in the bone marrow and a 3-fold increase in spleen

• however, activation of mTOR in response to IL-15 stimulation is normal in immature NK cells

impaired natural killer cell mediated cytotoxicity ( J:280182 )

• mice exhibit reduced clearance of MHC class I-deficient tumors in vivo; 48 h after i.p. injection, recovery of RMA/s tumor cells is 6.5% versus 1.8% in control mice

• in an in vitro YAC-1 target lysis assay, splenic NK cells (DX5+) show 53% of the cytotoxic activity seen in control mice at a 2:1 E:T ratio